ECSP23017104A - Procesos e intermedios para la preparación de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida - Google Patents

Procesos e intermedios para la preparación de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida

Info

Publication number
ECSP23017104A
ECSP23017104A ECSENADI202317104A ECDI202317104A ECSP23017104A EC SP23017104 A ECSP23017104 A EC SP23017104A EC SENADI202317104 A ECSENADI202317104 A EC SENADI202317104A EC DI202317104 A ECDI202317104 A EC DI202317104A EC SP23017104 A ECSP23017104 A EC SP23017104A
Authority
EC
Ecuador
Prior art keywords
methoxybenzamido
trifluoropropan
carboxamide
pyrazole
intermediates
Prior art date
Application number
ECSENADI202317104A
Other languages
English (en)
Inventor
Nicholas Andrew Magnus
Roger Ryan Rothhaar
Radhe Krishan Vaid
Stacey Renee Spencer
Elizabeth Ann Mcfaddin
Scott Alan Frank
Jared Wade Fennell
Delgado Alonso Jose Arguelles
Charles Todd Eary
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of ECSP23017104A publication Critical patent/ECSP23017104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/30—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona procesos e intermedios clave para la síntesis de (S)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1H-pirazol-4-carboxamida:
ECSENADI202317104A 2020-09-10 2023-03-09 Procesos e intermedios para la preparación de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida ECSP23017104A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063076577P 2020-09-10 2020-09-10

Publications (1)

Publication Number Publication Date
ECSP23017104A true ECSP23017104A (es) 2023-04-28

Family

ID=78080458

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202317104A ECSP23017104A (es) 2020-09-10 2023-03-09 Procesos e intermedios para la preparación de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida

Country Status (17)

Country Link
US (1) US20230322682A1 (es)
EP (1) EP4211117A1 (es)
JP (1) JP7547622B2 (es)
KR (1) KR20230065307A (es)
CN (1) CN116323553A (es)
AR (1) AR123427A1 (es)
AU (2) AU2021342132B2 (es)
BR (1) BR112023002873A2 (es)
CA (1) CA3189884A1 (es)
CL (1) CL2023000666A1 (es)
CO (1) CO2023002865A2 (es)
EC (1) ECSP23017104A (es)
IL (1) IL301103A (es)
MX (1) MX2023002890A (es)
PE (1) PE20231013A1 (es)
TW (2) TWI809489B (es)
WO (1) WO2022056100A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib
WO2024179558A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Pirtobrutinib的晶型及其制备方法和用途
WO2024194890A1 (en) * 2023-03-20 2024-09-26 Dr. Reddy’S Laboratories Limited Solid state forms of pirtobrutinib and process for the preparation of intermediate thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008381A0 (en) * 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
CN114591242A (zh) 2015-12-16 2022-06-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
CN107382973B (zh) * 2016-05-16 2020-08-07 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物
CN107652294A (zh) * 2017-11-14 2018-02-02 安徽诺全药业有限公司 一种伊鲁替尼的制备方法
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제

Also Published As

Publication number Publication date
TW202225146A (zh) 2022-07-01
TW202317099A (zh) 2023-05-01
PE20231013A1 (es) 2023-07-05
MX2023002890A (es) 2023-04-04
JP2023540802A (ja) 2023-09-26
CA3189884A1 (en) 2022-03-17
AR123427A1 (es) 2022-11-30
EP4211117A1 (en) 2023-07-19
AU2021342132A1 (en) 2023-04-13
JP7547622B2 (ja) 2024-09-09
CN116323553A (zh) 2023-06-23
AU2021342132B2 (en) 2024-05-23
WO2022056100A1 (en) 2022-03-17
IL301103A (en) 2023-05-01
CO2023002865A2 (es) 2023-03-27
BR112023002873A2 (pt) 2023-03-21
TWI809489B (zh) 2023-07-21
US20230322682A1 (en) 2023-10-12
CL2023000666A1 (es) 2023-08-18
AU2024202587A1 (en) 2024-05-09
KR20230065307A (ko) 2023-05-11

Similar Documents

Publication Publication Date Title
ECSP23017104A (es) Procesos e intermedios para la preparación de (s)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1h-pirazol-4-carboxamida
CO2021003900A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap
EA202091893A1 (ru) Новые кристаллические формы
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
MD3864003T2 (ro) Modulatori de promedicamente ai căii integrate de răspuns la stres
MX2022000504A (es) Polimorfos de (r)-n-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1 h-inden-1-il)-1-metil-1h-pirazol-4-carboxamida.
MA45130B1 (fr) Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein
HK1092152A1 (en) Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
CY1123893T1 (el) Αμιδια πυρρολης ως αναστολεις ιντεγκρινων αλφα v
CY1113547T1 (el) Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
EA201071238A1 (ru) Замещённое карбинольное соединение, содержащее циклический линкер
CL2021002167A1 (es) Síntesis de omecamtiv mecarbil (divisional de la solicitud no. 201903898)
EA200701588A1 (ru) Способы получения замещённых фенилпиразолмочевин
CY1125017T1 (el) Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho
EA202192320A1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида
BR112021020508A2 (pt) Inibidor de jak de 7h-pirrolo[2,3-d]pirimidina
EA202190663A1 (ru) Кристаллические формы агониста фарнезоидного х-рецептора
CY1112718T1 (el) Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης
CL2024000248A1 (es) Composiciones y métodos para anticuerpos anti-pacap
ECSP055692A (es) Proceso para preparar intermediarios
CO2023002124A2 (es) Alcaloide indólico con efecto fungicida
CO2022001513A2 (es) Proceso e intermediarios para la preparación de piroxasulfona
CY1124940T1 (el) Αλας διμεθυλαμινοαιθανολης ενος ρυθμιστη του υποδοχεα glp-1
UY29657A1 (es) Derivados de n-((1,5-difenil-1h-pirazol-3-il)metil)sulfonamida, su preparación y su aplicación en terapéutica